UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2018

Commission File Number 001-35463
 
Taro Pharmaceutical Industries Ltd.
 
(Translation of registrant’s name into English)

14 Hakitor Street, Haifa Bay 2624761, Israel
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F   ☒     Form 40-F   ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  Yes   ☐     No   ☒


  
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____.
 
 

 
 

 

 

 

 

 
Taro Pharmaceutical Industries Ltd.
c/o Taro Pharmaceuticals U.S.A., Inc.
Three Skyline Drive
Hawthorne, New York 10532
(NYSE: TARO)
 
 
 
 
CONTACTS:
Mariano A. Balaguer 
William J. Coote
VP, CFO 
AVP, Business Finance, Treasurer and Investor Relations
(914) 345-9001 
(914) 345-9001
Mariano.Balaguer@taro.com 
William.Coote@taro.com


FOR IMMEDIATE RELEASE

TARO ANNUAL REPORT ON FORM 20-F AVAILABLE
For Fiscal Year Ended March 31, 2018


 
Hawthorne, NY, June 22, 2018 – Taro Pharmaceutical Industries Ltd. (NYSE: TARO, “Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2018, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com.
 
Hard copies of the report may be ordered free of charge by sending requests to:

Taro Pharmaceuticals U.S.A., Inc.
3 Skyline Drive
Hawthorne, NY 10532
attention: William J. Coote or
via email to William.Coote@Taro.com
 

 
 
Additionally, the report may be accessed on the SEC’s website at www.sec.gov.
 


****
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit Taro’s website at www.taro.com.


# # #
 
 
 
SIGNATURES

 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Date: June 22, 2018
 
TARO PHARMACEUTICAL INDUSTRIES LTD.


By:   /s/ Uday Baldota
        Name:  Uday Baldota
         Title:    Chief Executive Officer and Director